Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
Get breaking news and incisive analysis sent to your inbox. Choose from a number of free newsletter options at MarketWatch, including Need to Know, which provides a guide to the trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results